1. Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, Stiller MJ. Effect of onychomycosis on quality of life. J Am Acad Dermatol. 1998 May;38(5 Pt 1):702-4.
2. Scott-Levin PDDA. November 2003.
3. Zaias N, Battistini F, Gomez-Urcuyo F, et. al. Cutis 1978;22:197-199.
4. Stedman’s Medical Dictionary, 27th ed. Lippincott, Williams and Wilkins, 2000.
5. Tosti A, Piraccini BM, Stinchi C, Colombo MD, Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 1998;162-66.
6. Heikkila H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol. 2002 Feb;146(2):250-3.
7. Gupta AK, Humke S. The prevalance and management of onychomycosis in diabetic patients. Eur J Dermatol 2000;10:379-384.
8. Data on file, Novartis Pharmaceuticals Corporation.
9. Notling S. Onychomycoses and their successful therapy. Wien Med Wochenschr. 1989; 139:354-355.
10. Evaluation of the mycological cure rates when ciclopirox nail lacquer is used in combination with oral terbinafine to treat toenail onychomycosis: six-month interim results. J Am Acad Dermatol Suppl March 2004;50(3):104.
11. Gianesterus NJ. Foot disorders. Medical and surgical management. 2nd edition. London: Henry Kimpton Publisher. 435, 1973.
12. Dominguez-Cherit J, Teixeitra F, Arenas R. Combined surgical and systematic treatment of onychomycosis. Br J Dermatol 1999.
13. Gupta AK, Jarratt M, Swinyer L, Babel D, Aly R: Mycologic response to terbinafine treatment of severe onychomycosis with or without ciclopirox 8% nail lacquer: Interim result poster at the 61st Annual Meeting of the American Academy of Dermatology, March 21-26, 2003.
14. Seebacher C. Neitsch KH, Albright H A multicenter, open label study of the efficacy of ciclopirox nail lacquer 8% for the treatment of onychomycosis in patients with diabetes. Cutis 2001;68(2 Supp): 17-22
15. Boulton AJ, Vileikyte L. The diabetic foot: the scope of the problem [In Process Citation]. J Fam Pract 49:S3-8, 2000.
16. Armstrong DG. Is diabetic foot care efficacious or cost-effective? Ostomy Wound Manage 47:28-32, 2001.
17. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Heagerty PJ. Prediction of diabetic foot ulcer using readily available clinical information: the Seattle Diabetic Foot Study. Diabetes 51 (Suppl2):A18, 2002.
18. Elewski BE, el Charif M, Cooper KD, et. al. Reactivity to Trichophyton antigen in patients with onychomycosis: effect of terbinafine. J Am Acad Dermatol 2002 Mar; 46(3):371-5.
19. Doyle JJ, et. al. Onychomycosis among diabetes patients: prevalence and impact of nonfungal foot infections. Presented at the American Diabetes Association’s 60th scientific seminar; June 9-13, 2000; San Antonio, Texas.
20. Bofeli TJ, Bean JK, Natwick GAR. Biomechanical abnormalities in ulcers of the great toe in patients with diabetes. JFAS 2002; 41(6):359-364.
21. Peters EJ, Lavery LA. Effectiveness of the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. Diabetes Care 24:1442-1447, 2001.
22. Jansen R, Redekop WK, Rutten FFH. Cost effectiveness of continuous terbinafine compared with intermittent itraconzaole in the treatment of dermatophyte toenail onychomycosis: an analysis based on results from the L.I.O.N. study. Pharmacoeconomics 2001; 19(4):401-410.
23. Sigurgeirsson B, Olafsson JH, Steinsson J, et. al. Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol. 2002;138:353-357.
24. Fuchs A, et. al. Frequency of culture-proven dermatophyte in patients with suspected tinea pedis. Am J Med Sci. 2004 Feb;327(2):77-78.
25. Scherer WP, Kinmon K. Dermatophyte test medium culture vs. mycologic laboratory analysis for suspected onychomycosis. A study of 100 cases in the geriatric population. JAPMA 200:90:450-459.